SteadyMed Ltd. Launches Initial Public Offering

SAN RAMON, Calif., March 9, 2015 (GLOBE NEWSWIRE) -- SteadyMed Ltd., a specialty pharmaceutical company, today announced the launch of its initial public offering of 4,250,000 ordinary shares at an anticipated initial public offering price between $12.00 and $14.00 per share. In addition, the company will grant the underwriters a 30-day option to purchase from SteadyMed up to an additional 637,500 shares. SteadyMed has applied to list its shares on The NASDAQ Global Market under the symbol "STDY".

Wells Fargo Securities, LLC and RBC Capital Markets, LLC are acting as joint book-running managers for the proposed offering. JMP Securities LLC is acting as lead manager. The offering will be made only by means of a prospectus. A copy of the preliminary prospectus, when available, may be obtained from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, NY 10152, or by telephone at (800) 326-5897, or by email at [email protected]; or from RBC Capital Markets, Attention: Prospectus Department, 200 Vesey Street 8th Floor, New York, NY 10281, or by phone at (877) 822-4089 or by emailing [email protected].

A registration statement relating to the shares has been filed with the Securities and Exchange Commission but has not yet become effective. The shares may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead candidate is Trevyent®, a development stage drug product that utilizes SteadyMed's PatchPump® technology to administer treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension. PatchPump is a proprietary, disposable, parenteral drug administration platform that is prefilled and preprogrammed at the site of manufacture. SteadyMed has offices in San Ramon, California and Rehovot, Israel.

CONTACT: Marylyn Rigby
         Director, Investor Relations and Marketing
         925-272-4999
         [email protected]

         Robert H. Uhl
         Managing Director
         Westwicke Partners
         858-356-5932
         [email protected]

You May Also Be Interested In

• Jersey Mike's files for IPO, plans NYSE listing under ticker JMKE
• Gold Resource shareholders approve merger with Goldgroup Mining
• Enanta Pharmaceuticals sets up $75M at-the-market stock offering